Connect with us

Cannabis News

Digipath’s GroSciences’ TERPO+ Broadspectrum Tests Advance For Its Plant-Derived Pesticide

Angie N

Published

on

Digipaths-GroSciences-Moves-Further-With-Testing-For-Its-Patent-Pending-Plant-Derived-Pesticide

Independent testing laboratory and formulation firm Digipath, Inc. has announced that its GroSciences division has completed preliminary validation testing on its natural plant-derived pesticide TERPO+ Broadspectrum that awaits patenting.

This product has the potential to serve a massive market and protect marijuana plants from microorganisms.

Testing has proven that TERPO+ Broadspectrum serves as a treatment for eliminating microbial bioburden on hemp and cannabis plants. Microbial bioburden and microorganism are the biggest contributors in cannabis plant loss.

Recent experiments on cannabis flower have shown that GroSciences’ TERPO+ Broadspectrum is effective in decontaminating cannabis and hemp plants, and ensures that cannabis samples are within most states’ testing limits.

Test results show that TERPO+ Broadspectrum reduced CFU/g with up to 91% compared to untreated samples.

According to the Chief Science Officer of Digipath Inc. Dr. Cindy Orser, the preliminary validation test successfully treated a sample that had failed a state microbial test previously.

After treatment with TERPO+ Broadspectrum, the sample passed the test.

Denkin said that a product like TERPO+ Broadspectrum could treat plants material effectively and help make it a sellable product with huge potential. He added that they would continue moving forward with product development and testing so that they can introduce it to the market soonest possible.

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

Join Us On Facebook

Advertisement

Trending CBD News

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

What Is CBD?

Advertisement